[The use of prostatilen in treating patients with prostatic diseases].
A clinical trial of polypeptide prostatic preparation prostatilen has been performed in 37 and 15 patients with chronic prostatitis and prostatic adenoma, respectively. The treatment resulted in attenuation of algetic and dysuria symptoms. Copulative function and spermatogenesis improved. The uroflowmetric index rose, while residual urine and leukocyte count in prostatic secretion reduced. The drug demonstrated antibacterial and immunomodulation effects in the absence of adverse reactions. Prostatilen is indicated in: chronic prostatitis, prostatic adenoma stage I, normospermatogenic and toxic sterility, interoceptive copulative dysfunction, dysuria. The drug in recommended for clinical application.
Vozianov
A F
AF
Gorpinchenko
I I
II
Boĭko
N I
NI
Drannik
G N
GN
Khavinson
V Kh
VKh
D000328:Adult; D000368:Aged; D002908:Chronic Disease; D006801:Humans; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000627:therapeutic use*; D011469:Prostatic Diseases / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D012074:Remission Induction; D013076:Sperm Count / Q000187:drug effects
D010455:Peptides; C053892:cytomedins; C069549:prostatilen
Primenenie prostatilena pri lechenii bol'nykh s zabolevaniiami predstatel'noĭ zhelezy.